Viking Therapeutics posts corporate presentation on obesity drug VK2735 Phase 3 program

Viking Therapeutics, Inc.

Viking Therapeutics, Inc.

VKTX

0.00
  • Viking Therapeutics highlighted VK2735 injectable obesity program with VANQUISH Phase 3 registration studies underway.
  • Company set start of Phase 3 obesity studies for oral VK2735 in 4Q26.
  • VENTURE Phase 2a obesity trial for oral VK2735 showed up to 12.2% mean weight loss at Week 13, versus 1.3% for placebo.
  • Viking planned Phase 1 start for VK3019 amylin agonist obesity candidate in 2Q26.
  • Pipeline update cited VK2809 MASH program with Phase 2b VOYAGE trial successfully completed, alongside VK0214 X-ALD program with Phase 1b proof-of-concept.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief on April 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.